Appendix 4C - quarterly
Filed with ASX · · 7 pages · English
® Q1 highlights: • A second clinical site was established for the Phase I HER2 Breast Cancer Study • Initiation of research for prostate cancer imaging supported by CSIRO funds • Secured new premises from November 2021 enabling increased manufacturing capabilities MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, today rele
Imagion Biosystems Ltd. on 6ix
Earlier from Imagion Biosystems
- IBX raises $6M in placement
- Appendix 4C & Quarterly Activity Report
- Imagion announces HREC approval for Phase I study
- Appendix 4D and Half Year Results H1 2020
- IBX raises $5M in oversubscribed placement
Later from Imagion Biosystems
- First-in-human study update - First patient enrolled
- 2020 R&D Tax Refund
- Half-year results release
- Full Year Results Release
- First-in-human Study Progress Update
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems